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BY-NC-ND license (http://creativecomBackground/Purpose: Little is known about the annual changes in cancer incidence and sur-
vival that occurred after the establishment of the long-form cancer registry database in
Taiwan. Therefore, this study aimed to investigate the updated incidence and stage-specific
relative survival rates (RSRs) among adult cancer patients in Taiwan.
Methods: Cancer incidence data from 2002 to 2012 were collected using the Taiwan Cancer
Registry Database. Age-standardized incidence rates, average annual percent changes
(AAPCs), and sex ratios were calculated for adults. Five-year stage-specific RSRs were esti-
mated for cases diagnosed between 2004 and 2008 and were followed up to 2013 for major
cancers.
Results: The overall age-standardized incidence rates per 100,000 populations increased
from 348.39 in 2002 to 401.18 in 2012, and the AAPC was 1.7% (p < 0.05), whereas the mal-
e:female ratio was approximately 1:3 during the entire period. Most cancer sites showed a
trend of increasing incidence, with the exception of common cancers such as cervix uteri
(AAPC Z 6.2%, p < 0.05), bladder (AAPC Z 2.5%, p < 0.05), stomach (AAPC Z 2.4%,
p < 0.05), nasopharynx (AAPC Z 1.2%, p < 0.05), and liver (AAPC Z 1.1%, p < 0.05).
The 5-year RSRs for Stage I cancers were greater than 93% for the colon and rectum, female
breast, and cervix uteri, whereas RSRs for patients with Stage IV cancers ranged from 2.9% to
38.9%, with patients with liver cancer and those with oral cancer showing the lowest and
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Incidence and survival of adult cancer patients 1077Conclusion: Our study showed increased incidence in most cancers and provided baseline es-
timates of stage-specific RSRs among the Taiwanese adult population. Continuous surveil-
lance may help politicians to improve health policies and cancer care in Taiwan.
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Cancer has been the leading cause of death in Taiwan for
>30 years.1 Cancer surveillance is indispensable for the
implementation of evidence-based cancer control pro-
grams, and population-based cancer registries provide
informative data for cancer surveillance. In Taiwan, a
nationwide cancer registry database has been established
since 1979, and the data quality of the cancer registry
database has been sustained at an excellent level since the
enactment of the Cancer Control Act in 2003.2
The Taiwan Cancer Registry (TCR) publishes national
cancer statistics annually, including incidence, mortality,
and distributions of treatment patterns for all cancer sites.
After the long-form cancer registry database was set up to
collect cancer staging information in 2002,2 the distribu-
tions of stage at diagnosis for major cancers was recently
published in the annual report.3 Although a previous study
presented the secular trends of cancer incidence for most
adult cancers,4 this report did not include the annual
changes in incidence. Additionally, a large international
comparison of cancer survival in 67 countries including
Taiwan was reported in 2015.5 However, very little infor-
mation exists on cancer survival according to stage at
diagnosis, which uses national cancer registry databases in
Taiwan. Therefore, this study aimed to provide updated
incidence rates and stage-specific survival rates among
adult cancer patients who received a cancer diagnosis be-
tween 2002 and 2012 in Taiwan.Methods
Data sources and quality
All newly diagnosedmalignant cancers fromhospitalswith 50
or more beds have been reported to the TCR since 1979.
Details of the history, objectives, and activities of the TCR
have been previously documented.2 After theCancer Control
Act was promulgated in 2003, the data quality and
completeness of the cancer registry database have improved
and have remained stable until now (Figure 1). For the most
recent data in 2012, the completeness of the TCR database
was 98.4%, the morphological verification percentage (MV%,
the proportion of incident cases with histological and/or
cytological verification of cancer diagnosis) was 91.5%, the
mortality versus incidence ratio (M/I, crude mortality rate
divided by the crude incidence rate of the invasive cancer)
was 45.2%, and the death certificate only percentage (DCO%,
the proportion of incident cases with information gathered
only from death certificates) for all cancer sites was 0.7%.This implies that the national cancer registry is indeed a high-
quality database, as shown in previous studies.2,4
All invasive cancer cases diagnosed in adults aged 15
years and older from 2002 until 2012 were included in this
analysis. Cancer sites have been coded in Taiwan by
anatomical site (tomography) and morphology according to
the International Classification of Disease for Oncology 3rd
Edition6 (ICD-O-3) since 2002. All hematopoietic and
lymphoid malignant neoplasms were defined by the ICD-O-3
morphology codes ranging from 9590 to 9992 and presented
separately from each site. Classification of oral cavity,
oropharynx, and hypopharynx was defined using the codes
from the Head and Neck Surgery and Oncology, 3rd Edition,7
and grouped by the following ICD-O-3 tomography codes:
oral cavity (C00eC06 excluding C01, C02.4, C05.1, and
C05.2), oropharynx (C01, C02.4, C05.1, C05.2, C09eC10,
C14.2, and C14.8), and hypopharynx (C12, C13, and C14.0).
Cancer staging data collected in the long-form database
used the TNM staging system,8 which was derived by the
American Joint Committee on Cancer (AJCC) and the Inter-
national Union Against Cancer (UICC), for six major cancers
of the oral cavity and pharynx (oral cavity, oropharynx, and
hypopharynx), colon and rectum, liver, lung, breast, and
cervix uteri. For survival analysis, we included only major
histological subtypes of the selected cancers diagnosed from
2004 until 2008 (shown in Table 1), for which the vital status
of patients was followed up until December 31, 2013. Stag-
ing data collected between 2002 and 2003 were excluded,
because the long-form database was still in the pilot phase.2
We included patients in whom two or more primary
cancers were diagnosed at different sites between 2004 and
2008 and were included in the analyses for each cancer
(i.e., breast cancer in 2004, lung cancer in 2008). When two
or more primary cancers occurred at the same site between
2004 and 2008, only the first cancer was included. Passive
follow-up was conducted using the national death certifi-
cate database maintained by the Department of Statistics,
Ministry of Health and Welfare, Taiwan. The duration of
survival for each case was determined as the time from the
date of initial diagnosis to the date of death, or date of
follow-up termination, whichever came first. Records were
excluded if the date of birth or death was unknown.Statistical analysis
Crude rates and age-standardized rates (ASRs) of incidence
were estimated for all and each cancer from 2002 until 2012.
ASRs were calculated by the direct method using the 2000
world standard population as defined by the World Health
Organization9 and expressed as cases per 100,000 pop-
ulations. Trends in annual ASRs were analyzed using the
annual percent change (APC) by joinpoint regression analysis
Figure 1 Data quality indicators of the Taiwan Cancer Registry Database after the enactment of the Cancer Control Act.
Completeness (%) Z all registered cancer cases divided by all potential cancer cases taken from the national death certificate
database, National Health Insurance catastrophic illnesses database, and four cancer screening programs; Percentage of
morphological verification (MV) Z the proportion of incident cases with histological and/or cytological verification of cancer
diagnosis; Mortality versus incidence (M/I) ratio (%)Z crude mortality rate divided by crude incidence rate of the invasive cancer
during the same period; Percentage of death certificate only (DCO) Z the proportion of incident cases with diagnosis information
based on death certificates only.
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tional Cancer Institute, Bethesda, MD, USA).10 The best-
fitting trend lines where the rate changed significantly were
chosen by Monte Carlo permutation tests.11 To quantify the
incidence trend, the average annual percentage change
(AAPC) and confidence intervals (CIs) were calculated by all
sites, each site, and sex. The significance of AAPC does not
include zero (p < 0.05). The sex ratio was estimated by the
ratio of the ASR among males to the ASR among females.
Relative survival is a net survival measure representing
the cumulative probability that cancer patients would have
survived a given time in the hypothetical situation where
other causes of death were absent. Relative survival rates
(RSRs) were estimated by dividing observed survival by
expected survival among comparable groups in the general
population that were similar to the patient group with
respect to age, sex, and calendar year of observation.12
The RSRs were calculated by the Ederer II method using
the cohort approach.13 A RSR of 100% indicates that a
cancer patient group is just as likely to survive the given
interval as a comparable group in the general population of
the same sex and age; it does not, however, imply thateveryone in the group has survived cancer. Additionally,
age-standardized RSRs were also provided for future in-
ternational comparisons using the International Cancer
Survival Standard (ICSS) weights.14
Stage at diagnosis was classified as IeIV or unknown. The
choice of final stage data depended on the best available
information on the stage of disease: if no preoperative
therapy was performed, the pathologic stage was used; if
neoadjuvant therapy was conducted, the clinical stage took
priority in most cases. All estimates and CIs for unstan-
dardized and age-standardized RSRs were calculated by
final stage and sex for selected cancers during 2004e2008.
All analyses were performed using SAS version 9.3 (SAS
Institute, Cary, NC, USA).
Results
Incidence
The number of cases, crude and age-standardized inci-
dence rates, average annual percentage change, and sex
Table 1 Definition of major cancers selected for survival analysis from the long-form cancer registry database.a
Site ICD-O-3 topography codesb Selected histological type ICD-O-3 morphology codesb
Oral cavityc C00eC06 excludes C01,
C02.4, C05.1 and C05.2
Squamous cell carcinoma 8032, 8052, 8070e8083
Oropharynxc C01, C024, C051, C052,
C09eC10, C142, C148
Squamous cell carcinoma 8032, 8052, 8070e8083
Hypopharynxc C12eC13, C140 Squamous cell carcinoma 8032, 8052, 8070-8083
Colon C18 Adenocarcinoma 8140e8145, 8200e8221, 8255e8263,
8310e8332, 8440, 8470e8490
Rectum C19eC20 Adenocarcinoma 8140e8145, 8200e8221, 8255e8263,
8310e8332, 8440, 8470e8490
Liver C22 Hepatocellular carcinoma 8170e8175
Lung C34 Non-small cell carcinoma All excluding 8041e8045
Female breast C50 All types excluding phyllodes tumor All excluding 9020
Cervix uteri C53 All types All
a All sites excluded Kaposi’s sarcoma, hematopoietic and lymphoid neoplasms.
b ICD-O-3, International Classification of Diseases for Oncology, 3rd edition.
c Classification for oral cavity, oropharynx, and hypopharynx was done using the codes from the Head and Neck Surgery and Oncology,
3rd Edition.
Incidence and survival of adult cancer patients 1079ratios by all sites combined and each individual site are
shown in Table 2. The overall age-standardized incidence
rate (per 100,000 populations) of cancer among adults in
Taiwan increased from 348.39 in 2002 to 401.18 in 2012.
The AAPC for all sites combined was 1.7% (95% CI:
1.2e2.2%) and the male:female sex ratio was approxi-
mately 1:3 during the study period.
Most cancer sites showed a trend of increasing inci-
dence, with the exception of cancers of the cervix uteri
(AAPC Z 6.2%; p < 0.05), other ill-defined and unknown
sites (AAPC Z 4.6%; p < 0.05), bladder (AAPC Z 2.5%;
p < 0.05), stomach (AAPCZ 2.4%; p < 0.05), male breast
(AAPC Z 2.4%), other urinary organs (AAPC Z 2.3%),
anus (AAPC Z 1.8%), other endocrine organs
(AAPC Z 1.2%), nasopharynx (AAPC Z 1.2%; p < 0.05),
liver and intrahepatic bile ducts (AAPCZ 1.1%; p < 0.05),
larynx (AAPC Z 0.6%), and gallbladder (AAPC Z 0.2%).
The five leading solid cancers that significantly increased in
this period were corpus uteri (AAPC Z 6.7%), thyroid
(AAPC Z 6.4%), prostate (AAPC Z 5.6%), oropharynx
(AAPC Z 5.0%), and female breast (AAPC Z 4.9%). Among
hematopoietic and lymphoid neoplasms, the incidence of
myeloproliferative neoplasms showed the most rapid in-
crease (AAPC Z 7.5%; p < 0.05), followed by lymphoid
leukemia (AAPCZ 4.3%; p < 0.05), and Hodgkin lymphoma
(AAPC Z 3.7%; p < 0.05).
According to the analyses of sex ratios in Table 2, can-
cers of the oral cavity, oropharynx, hypopharynx, esoph-
agus, and larynx showed a strong male predominance
(male:female ratio >10). Conversely, breast and thyroid
cancers showed a strong female predominance (mal-
e:female ratio < 0.5). In order to present the secular trends
and AAPC of incidence according to sex during the period
from 2002 to 2012, selected sites with more than 550 inci-
dent cases in 2002 and with a significant AAPC% are shown
in Figure 2, sorted by the size of the AAPC value.
With regard to the aging population in recent years, it is
necessary to evaluate the condition among the elderly
(aged 65 years and older). The incidence rates and averageannual percentage change for the top five increasing and
decreasing cancers among the elderly are shown in Table 3.
The overall age-standardized incidence rates (per 100,000
populations) of cancer among the elderly increased from
1,437.41 in 2002 to 1,595.35 in 2012, and the AAPC in this
period was 1.4% (95% CI: 0.8e2.1%). The five leading can-
cers that significantly increased in the elderly population
were breast (AAPC Z 7.9%), corpus uteri (AAPC Z 6.4%),
oral cavity (AAPC Z 5.6%), prostate (AAPC Z 5.4%), and
oropharynx (AAPC Z 4.4%); whereas the top five signifi-
cantly decreased sites were cervix uteri (AAPC Z 7.4%),
stomach (AAPC Z 2.7%), bladder (AAPC Z 2.1%),
nasopharynx (AAPCZ 1.6%), and larynx (AAPCZ 1.4%).Survival
Table 4 shows the distribution of AJCC staging, and 5-year
crude and age-standardized RSRs according to sex of nine
major cancers for the period between 2004 and 2008.
Cancers of the oral cavity, oropharynx, hypopharynx, colon,
rectum, liver, and lung were found to be more frequent in
males than in females, especially for cancers of the oral
cavity and pharynx (>90% cases were male sex). Regarding
the stage at diagnosis, most cancers, including the oral
cavity, oropharynx, hypopharynx, colon, rectum, and lung,
were diagnosed at advanced stages (Stages IIIeIV), whereas
liver, female breast, and cervical cancers were diagnosed
at early stages (Stages IeII). Of the nine cancers examined,
hypopharyngeal cancer was the most severe, with 72.7% of
cases identified as Stage IV, compared to only 6% of female
breast cancers. AJCC stage was unknown in 2.4e19.6% of
individuals, varying by cancer types.
The overall 5-year crude RSR was the highest for female
breast cancer (86.1%) and the lowest for lung cancer
(16.3%; Table 4). For cancers of the colon, rectum, female
breast, and cervix uteri, the 5-year RSRs for Stage I disease
were >93%. Conversely, the 5-year RSRs for hypopharyngeal
and liver cancers were only 44.5% and 52.0%, respectively.
Table 2 Number of cases, incidence rates, average annual percentage change, and gender ratios of all types of cancer
patients aged 15 years and older in Taiwan, 2002e2012.
ICD-O-3 Site Incidence rate (/106) in 2002 Incidence rate (/106) in 2012 AAPC%a (95% CI)
Cases CR ASR Sex
ratio
Cases CR ASR Sex
ratio
C00eC80 All sites 62,555 349.04 348.39 1.36 96,245 483.54 401.18 1.30 1.7 (1.2,2.2)
C00eC06,
C09eC10,
C12eC14b
Oral cavity 2,668 14.89 14.69 8.87 4,715 23.69 20.27 10.16 2.9 (2.1,3.8)
Oropharynx 623 3.48 3.50 11.73 1,321 6.64 5.60 11.64 5.0 (3.6,6.4)
Hypopharynx 555 3.10 3.11 29.95 1,009 5.07 4.24 47.17 4.0 (2.5,5.5)
C07eC08 Salivary glands 172 0.96 0.94 1.35 285 1.43 1.27 1.31 3.3 (1.2,5.4)
C11 Nasopharynx 1,412 7.88 7.67 3.26 1,576 7.92 6.96 3.41 L1.2 (L1.6,L0.7)
C15 Esophagus 1,310 7.31 7.40 10.02 2,372 11.92 9.84 13.57 3.2 (2.2,4.1)
C16 Stomach 3,692 20.60 20.44 1.98 3,795 19.07 15.03 1.81 L2.4 (L3.1,L1.7)
C17 Small intestine 255 1.42 1.44 1.71 348 1.75 1.45 1.43 0.2 (0.9,1.3)
C18 Colon 4,576 25.53 25.46 1.28 9,299 46.72 37.72 1.28 4.3 (3.2,5.3)
C19eC20 Rectum 3,589 20.03 20.16 1.38 5,559 27.93 22.84 1.78 1.4 (0.7,2.1)
C21 Anus 86 0.48 0.48 0.90 101 0.51 0.42 0.95 1.8 (5.6,2.1)
C22 Liver & intrahepatic
bile ducts
9,578 53.44 54.34 2.52 11,398 57.26 47.11 2.50 L1.1 (L1.7,L0.5)
C23eC24 Gallbladder 720 4.02 4.06 1.03 934 4.69 3.75 1.24 0.2 (1.5,1.2)
C25 Pancreas 1,104 6.16 6.18 1.35 1,893 9.51 7.66 1.43 2.5 (1.8,3.2)
C30eC31 Nose, nasal cavity
& middle ear
154 0.86 0.85 1.74 206 1.03 0.87 1.89 0.8 (1.2,2.8)
C32 Larynx 539 3.01 3.03 19.72 656 3.30 2.71 17.03 0.6 (1.5,0.2)
C33eC34 Lung, bronchus and
trachea
7,367 41.11 40.98 1.94 11,690 58.73 47.32 1.64 1.6 (1.0,2.2)
C37eC38 Other thoracic organs 195 1.09 1.07 1.37 338 1.70 1.48 1.79 3.4 (1.4,5.5)
C40eC41 Bone & joints 140 0.78 0.82 1.17 151 0.76 0.77 1.68 0.7 (1.9,3.3)
C44c Melanoma of skin 179 1.00 1.01 1.30 253 1.27 1.04 1.47 1.5 (0.9,3.9)
Nonmelanoma of skin 1,858 10.37 10.44 1.20 3,017 15.16 11.97 1.37 2.1 (0.9,3.3)
C47,C49 Connective tissue 383 2.14 2.13 1.44 496 2.49 2.27 1.34 1.4 (0.2,2.7)
C48 Retroperitoneum
& peritoneum
115 0.64 0.67 0.91 154 0.77 0.67 0.99 1.7 (0.7,4.2)
C50 Female breast 5,088 57.60 55.88 d 10,525 105.14 89.21 d 4.9 (4.2,5.6)
Male breast 38 0.42 0.41 d 34 0.34 0.29 d 2.4 (6.2,1.4)
C53 Cervix uteri 2,193 24.83 24.24 d 1,567 15.65 12.99 d L6.2 (L7.3,L5.1)
C54 Corpus uteri 786 8.90 8.79 d 1,936 19.34 16.18 d 6.7 (5.7,7.7)
C55 Uterus unspecified 5 0.06 0.06 d 15 0.15 0.13 d 4.3 (5.8,15.4)
C56 Ovary 790 8.94 8.80 d 1,180 11.79 10.30 d 1.8 (0.9,2.7)
C51eC52,
C57eC58
Vulva, vagina & other
female genital organs
121 1.37 1.36 d 220 2.20 1.75 d 1.2 (0.6,3.1)
C61 Prostate 2,383 26.22 25.61 d 4,735 47.86 40.19 d 5.6 (4.6,6.5)
C62 Testis 102 1.12 1.12 d 201 2.03 2.26 d 7.7 (6.2,9.1)
C60,C63 Penis & other male
genital organs
98 1.08 1.06 d 123 1.24 1.06 d 0.3 (4.2,4.9)
C64 Kidney 603 3.36 3.35 1.82 1,210 6.08 5.09 2.19 4.2 (3.5,4.8)
C65 Renal pelvis 475 2.65 2.71 0.87 699 3.51 2.87 0.87 1.0 (1.6,3.7)
C66 Ureter 272 1.52 1.54 0.71 466 2.34 1.90 0.82 1.6 (0.1,3.2)
C67 Bladder 1,794 10.01 10.01 2.43 2,001 10.05 7.96 2.62 L2.5 (L3.4,L1.6)
C68 Other urinary organs 220 1.23 1.23 1.51 225 1.13 0.90 1.01 2.3 (4.7,0.2)
C69 Eye 30 0.17 0.17 1.69 39 0.20 0.16 0.94 1.0 (1.1,3.3)
C70eC72 Brain & central
nervous system
544 3.04 3.01 1.32 685 3.44 3.14 1.32 1.0 (0.1,1.9)
C73 Thyroid 1,449 8.09 7.94 0.32 2,886 14.50 13.31 0.30 6.4 (5.1,7.6)
C74eC75 Other endocrine
organs
45 0.25 0.25 1.45 56 0.28 0.25 1.43 1.2 (4.3,2.0)
M-9650-9667 Hodgkin lymphoma 119 0.66 0.68 1.68 165 0.83 0.89 1.14 3.7 (2.0,5.4)
M-9590-9597,
M-9670-9727,
Non-Hodgkin
lymphoma
1,528 8.53 8.50 1.23 2,323 11.67 9.78 1.36 1.5 (1.0,2.1)
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Table 2 (continued )
ICD-O-3 Site Incidence rate (/106) in 2002 Incidence rate (/106) in 2012 AAPC%a (95% CI)
Cases CR ASR Sex
ratio
Cases CR ASR Sex
ratio
M-9735-9738,
M-9750-9764,
M-9826-9831,
M-9833-9834,
M-9940, 9948,
9971
M-9731-9734 Plasma cell
neoplasms
325 1.81 1.81 1.50 527 2.65 2.13 1.51 2.0 (1.2,2.8)
M-9728-9729,
M-9811-9818,
M-9835-9837,
9823
Lymphoid
leukemia
193 1.08 1.11 1.53 327 1.64 1.53 1.27 4.3 (3.1,5.4)
M-9840-9931,
M-9945-9946,
M-9963-9964
Myeloid leukemia 677 3.78 3.76 1.55 1,003 5.04 4.43 1.48 1.5 (0.9,2.2)
M-9800-9809,
M-9820, 9832
Other leukemias 32 0.18 0.18 2.89 35 0.18 0.15 0.88 0.2 (3.0,3.6)
M-9740-9742,
M-9950-9962,
M-9965-9967,
9975
Myeloproliferative
neoplasms
95 0.53 0.54 1.12 256 1.29 1.09 1.21 7.5 (3.5,11.6)
M-9980-9992 Myelodysplastic
syndromes
178 0.99 0.98 1.31 257 1.29 1.06 2.16 0.8 (1.7,3.2)
C26, C39, C76,
C80
Other ill-defined
and unknown sites
1,102 6.15 6.14 1.42 982 4.93 3.90 1.30 L4.6 (L5.6,L3.6)
AAPC Z average annual percentage change; ASR Z age standardized rate; CI Z confidence interval; CR Z crude rate; sex ratio, the
ratio of male over female age standardized rate.
a The average annual percentage change is significantly different from zero and shown in bold (p < 0.05).
b Classification for oral cavity, oropharynx, and hypopharynx was using the codes from the Head and Neck Surgery and Oncology, 3rd
Edition: oral cavity (C00eC06 excludes C01, C02.4, C05.1, and C05.2), oropharynx (C01, C02.4, C05.1, C05.2, C09eC10, C14.2, and
C14.8), hypopharynx (C12, C13, and C14.0).
c Melanoma of skin (ICD-O M-872-879); Nonmelanoma of skin (except for ICD-O M-872-879).
Incidence and survival of adult cancer patients 1081Relative survival rates for patients with Stage IV cancers
ranged from 2.9% to 38.9%, with patients with liver cancer
showing the lowest RSR, and those with oral cancer showing
the highest RSR. With respect to sex differences, the
overall 5-year RSRs for cancers of the oral cavity,
oropharynx, colon, rectum, liver, and lung were similar or
higher in females (65.8%, 67.1%, 62.5%, 65.8%, 31.7%, and
21.0%, respectively) compared with males (60.0%, 40.2%,
62.5%, 62.1%, 28.1%, and 13.5%, respectively), whereas
those for hypopharyngeal cancer were slightly higher in
males (29.8%) than in females (25.2%). Additionally, the 5-
year stage-specific RSRs were similar in males and fe-
males for cancers of the oral cavity, colon, rectum, and
liver. In cases of lung cancer, females had a higher pro-
portion of Stage IV lung cancer than males, although the
survival rate for metastatic lung cancer was still higher in
females. Among patients with Stage IV oropharyngeal can-
cer, males had poorer survival rates than females.
The age-standardized RSRs are also shown in Table 4 for
future international comparison. All estimates of age-
standardized RSRs for the nine cancers were similar or
slightly lower than estimates of unstandardized RSRs. Thereason for this is that the distribution of diagnosis age for
all nine major cancers in the Taiwanese population was
younger than diagnosis ages in International Cancer Survival
Standard population (data not shown).Discussion
The major findings of this study were that cancers in adults
showed a trend of increasing incidence, with a significant
increase of 1.7% per year from 2002 to 2012, and that sex-
related incidence patterns differed according to the pri-
mary cancer site. In order to evaluate the possible effects
of a health policy on population-based survival in the
future, a baseline stage-specific survival rate for major
cancers is needed. The 5-year RSRs for Stage I cancers were
greater than 93% for the screened cancers, such as colon
and rectum, female breast, and cervix uteri; RSRs for pa-
tients with Stage IV cancers ranged from 2.9% to 38.9%,
with patients with liver cancer and those with oral cancer
showing the lowest and highest RSRs, respectively. This is
the first study that utilizes the population-based cancer
Figure 2 Incidence trends and average annual percentage changes for selected cancers in Taiwan by both sexes, from 2002 to
2012. Each circle represents the age standardized rate in each year and each panel represents the average annual percentage
change (%) with asterisks (*) indicating statistical significances (p < 0.05). Note that the scale of the y axis is different across panels
and the order of these panels is ranked by the size of the average annual percentage change value.
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Table 3 Number of cases, incidence rates, and average annual percentage change for the top five increasing and decreasing cancers among patients aged 65 years and older
in Taiwan, 2002e2012.
Site Incidence rate (/106) in 2002 Incidence rate (/106) in 2012 AAPC%a (95% CI)
Total Male Female Total Male Female Total Male Female
Cases ASR Cases ASR Cases ASR Cases ASR Cases ASR Cases ASR
All sites 29,497 1437.41 18,784 1777.25 10,713 1080.52 43,323 1595.35 25,994 2030.52 17,329 1211.19 1.4 (0.8,2.1) 1.8 (1.1,2.4) 1.5 (0.9,2.1)
Top five increasing cancersb
Breast 804 40.14 20 1.93 784 79.87 1995 80.85 20 1.55 1,975 151.33 7.9 (6.9,8.8) 1.6 (4.3,1.3) 7.3 (6.4,8.2)
Corpus uteri d d d d 135 13.74 d d d d 314 24.07 d d 6.4 (4.4,8.4)
Oral cavityc 456 22.54 359 34.87 97 9.79 894 36.17 715 62.50 179 12.86 5.6 (3.1,8.1) 6.7 (3.9,9.5) 2.0 (2.3,6.4)
Prostate d d 2075 194.27 d d 3845 140.00 3845 298.30 d d d 5.4 (4.4,6.3) d
Oropharynxc 123 6.17 110 10.94 13 1.31 217 8.80 191 16.65 26 1.84 4.4 (3.2,5.7) 5.3 (3.8,6.8) 3.2 (1.5,5.0)
Top five decreasing cancersb
Cervix uteri d d d d 691 69.97 d d d d 476 32.94 d d L7.4 (-8.7,6.0)
Stomach 2,324 112.61 1661 156.03 663 66.70 2296 79.97 1486 110.06 810 53.23 L2.7 (L3.3,-2.0) L2.8 (L3.5,-2.1) L1.6 (L2.4,-0.7)
Bladder 1158 56.28 826 77.79 332 33.51 1325 46.94 917 68.67 408 27.67 L2.1 (L2.9,-1.4) L1.6 (L2.6,-0.6) L2.1
(L3.2,L1.0)
Nasopharynx 211 10.45 158 15.22 53 5.43 249 10.00 197 16.86 52 3.98 L1.6 (L2.7,L0.6) 0.9 (2.3,0.6) 2.6 (5.5,0.3)
Larynx 286 13.94 274 26.08 12 1.20 293 11.25 267 21.85 26 1.84 L1.4 (L2.6,-0.2) 0.8 (2.1,0.5) 2.4 (1.7,6.7)
AAPC Z average annual percentage change; ASR Z age standardized rate; CI Z confidence interval.
a The average annual percentage change is significantly different from zero and shown in bold (p < 0.05).
b Top five increasing and decreasing cancers were ranked by the significant value of average annual percentage change in both sexes.
c Classification for oral cavity, oropharynx, and hypopharynx was using the codes from the Head and Neck Surgery and Oncology, 3rd
Edition: oral cavity (C00eC06 excludes C01, C02.4, C05.1, and C05.2), oropharynx (C01, C02.4, C05.1, C05.2, C09eC10, C14.2, and C14.8),
hypopharynx (C12, C13, and C14.0).
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Table 4 American Joint Committee on Cancer stage distribution, 5-year crude and age-standardized relative survival ra (%) with 95% confidence intervals for major
cancers by sex from 2004 to 2008 in Taiwan.
Site
Oral cavity Oropharynx Hypopharynx Colon Rectum Liver Lung Female
breast
Cervix
uteri
Stage distribution, n (%)
Total
Stage I 3971 (25.2) 406 (10.5) 130 (4.3) 2599 (12.7) 2850 (18.7) 11,601 (30. 3781 (11.4) d d
Stage II 3051 (19.4) 512 (13.3) 190 (6.3) 6172 (30.1) 3665 (24.0) 8668 (22. 1111 (3.4) d d
Stage III 1865 (11.8) 522 (13.5) 369 (12.1) 5831 (28.5) 4901 (32.1) 12,201 (31. 8625 (26.0) d d
Stage IV 6259 (39.7) 2190 (56.7) 2212 (72.7) 5025 (24.5) 2856 (18.7) 3482 (9.1 18,423 (55.6) d d
Unknown 606 (3.9) 231 (6.0) 140 (4.6) 850 (4.2) 993 (6.5) 2399 (6.3 1181 (3.6) d d
All stagesa 15,752 (100.0) 3861 (100.0) 3041 (100.0) 20,477 (100.0) 15,265 (100.0) 38,351 (100 ) 33,121 (100.0) d d
Males
Stage I 3562 (24.7) 390 (10.7) 126 (4.2) 1515 (13.5) 1585 (17.5) 7912 (28. 2162 (10.4) d d
Stage II 2794 (19.4) 476 (13.1) 186 (6.3) 3430 (30.5) 2254 (24.8) 6075 (21. 750 (3.6) d d
Stage III 1724 (11.9) 490 (13.5) 357 (12.0) 3100 (27.5) 2895 (31.9) 9630 (34. 5961 (28.6) d d
Stage IV 5817 (40.3) 2060 (56.7) 2165 (72.9) 2740 (24.3) 1760 (19.4) 2762 (9.8 11,159 (53.5) d d
Unknown 541 (3.7) 217 (6.0) 136 (4.6) 467 (4.2) 577 (6.4) 1682 (6.0 818 (3.9) d d
All stagesa 14,438 (100.0) 3633 (100.0) 2970 (100.0) 11,252 (100.0) 9071 (100.0) 28,061 (100 ) 20,850 (100.0) d d
Females
Stage I 409 (31.1) 16 (7.0) 4 (5.6) 1084 (11.7) 1265 (20.4) 3689 (35. 1619 (13.2) 8975 (30.0) 3488 (42.3)
Stage II 257 (19.6) 36 (15.8) 4 (5.6) 2742 (29.7) 1411 (22.8) 2593 (25. 361 (2.9) 12,350 (41.4) 1350 (16.4)
Stage III 141 (10.7) 32 (14.0) 12 (16.9) 2731 (29.6) 2006 (32.4) 2571 (25. 2664 (21.7) 6043 (20.2) 1189 (14.4)
Stage IV 442 (33.6) 130 (57.0) 47 (66.2) 2285 (24.8) 1096 (17.7) 720 (7.0 7264 (59.2) 1784 (6.0) 599 (7.3)
Unknown 65 (5.0) 14 (6.2) 4 (5.6) 383 (4.2) 416 (6.7) 717 (7.0 363 (3.0) 710 (2.4) 1612 (19.6)
All stagesa 1314 (100.0) 228 (100.0) 71 (100.0) 9225 (100.0) 6194 (100.0) 10,290 (100 ) 12,271 (100.0) 29,862
(100.0)
8238
(100.0)
5-year crude relative survival (95% CI)
Total d d
Stage I 83.6
(82.2e84.9)
64.6
(59.4e69.3)
44.5
(35.4e53.4)
95.4
(93.7e97.0)
93.1
(91.4e94.7)
52.0
(51.0e53.0
68.9
(67.1e70.7)
d d
Stage II 74.5
(72.8e76.2)
57.4
(52.8e61.9)
48.1
(40.3e55.6)
86.6
(85.3e87.9)
81.1
(79.4e82.8)
35.9
(34.8e37.0
40.1
(36.9e43.3)
d d
Stage III 57.1
(54.7e59.5)
47.2
(42.6e51.6)
41.3
(36.0e46.6)
67.4
(66.0e68.9)
64.7
(63.1e66.2)
11.0
(10.4e11.6
13.4
(12.6e14.2)
d d
Stage IV 38.9
(37.6e40.1)
32.4
(30.4e34.5)
25.2
(23.3e27.1)
12.3
(11.4e13.3)
12.7
(11.5e14.1)
2.9
(2.4e3.6)
5.5
(5.2e5.9)
d d
All stagesa 59.8
(59.0e60.6)
41.3
(39.7e42.9)
29.2
(27.5e30.9)
62.3
(61.5e63.1)
63.3
(62.4e64.2)
28.9
(28.4e29.3
16.3
(15.8e16.7)
d d
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2)
6)
8)
)
)
.0
2)
7)
3)
)
)
.0
8)
2)
0)
)
)
.0
)
)
)
)
Males
Stage I 83.8
(82.4e85.2)
64.5
(59.2e69.5)
44.2
(34.8e53.4)
95.9
(93.4e98.2)
93.6
(91.1e95.9)
53.2
(52.0e54.5)
61.9
(59.4e64.4)
d d
Stage II 75.4
(73.6e77.2)
58.3
(53.3e62.9)
49.5
(41.5e57.3)
87.0
(85.1e88.8)
81.4
(79.0e83.6)
36.9
(35.6e38.2)
35.1
(31.3e39.0)
d d
Stage III 57.4
(54.9e59.9)
45.6
(40.9e50.2)
42.6
(37.0e48.1)
66.3
(64.2e68.3)
63.5
(61.4e65.6)
10.9
(10.3e11.6)
11.0
(10.2e11.9)
d d
Stage IV 39.2
(37.9e40.5)
30.9
(28.8e33.0)
25.7
(23.8e27.6)
12.2
(10.9e13.5)
11.6
(10.0e13.2)
2.9
(2.3e3.6)
4.3
(3.9e4.7)
d d
All stagesa 60.0
(59.2e60.9)
40.2
(38.5e41.9)
29.8
(28.0e31.5)
62.5
(61.4e63.6)
62.1
(60.9e63.3)
28.1
(27.6e28.7)
13.5
(13.0e14.0)
d d
Females
Stage I 90.0
(85.8e93.4)
86.9
(56.1e100.)
79.3
(13.5e101.)
95.9
(93.5e98.0)
93.4
(91.0e95.6)
50.6
(48.8e52.4)
78.7 (
76.3e80.9)
98.4
(98.0e98.9)
93.1
(92.0e94.2)
Stage II 75.5
(68.9e81.4)
57.7
(39.5e72.7)
27.7
(1.0e73.6)
86.9
(85.0e88.7)
82.1
(79.4e84.6)
34.4
(32.5e36.4)
51.2
(45.5e56.6)
92.6
(92.0e93.2)
73.5
(70.7e76.1)
Stage III 61.4
(52.1e69.7)
81.3
(62.0e92.6)
26.5
(6.4e53.6)
69.0
(67.0e71.0)
67.1
(64.8e69.4)
12.0
(10.7e13.4)
18.8
(17.3e20.4)
73.7
(72.5e74.8)
58.7
(55.7e61.7)
Stage IV 40.6
(35.7e45.5)
63.0
(53.8e71.1)
22.1
(11.4e35.1)
12.6
(11.3e14.1)
14.7
(12.6e17.0)
3.3
(2.1e4.9)
7.3
(6.7e8.0)
25.7
(23.6e27.8)
22.0
(18.6e25.5)
All stagesa 65.8
(62.8e68.6)
67.1 (
60.2e73.2)
25.2
(15.6e36.2)
62.5
(61.3e63.6)
65.8
(64.4e67.1)
31.7
(30.8e32.7)
21.0
(20.3e21.8)
86.1
(85.7e86.6)
75.1
(74.0e76.1)
5-year age-standardized relative survival (95% CI)
Total
Stage I 83.3
(77.3e89.3)
65.7
(43.6e87.8)
47.2
(24.7e69.8)
95.4
(91.8e99.0)
93.1
(89.4e96.7)
49.6
(47.3e51.8)
67.8
(64.2e71.4)
d d
Stage II 68.5
(61.7e75.3)
54.3
(39.4e69.1)
46.7
(26.6e66.8)
86.9
(84.2e89.5)
81.0
(77.3e84.7)
34.0
(31.5e36.5)
40.4
(33.3e47.4)
d d
Stage III 50.4
(41.9e58.9)
44.8
(28.9e60.8)
43.1
(27.5e58.7)
67.0
(63.9e70.1)
63.8
(60.3e67.3)
10.7
(9.4e12.1)
14.0
(12.1e16.0)
d d
Stage IV 36.0
(31.7e40.4)
29.5
(22.6e36.5)
23.1
(17.6e28.7)
12.2
(10.0e14.3)
12.4
(9.6e15.2)
3.2
(1.7e4.6)
5.6
(4.8e6.4)
d d
All stagesa 56.6
(53.6e59.6)
38.6
(33.0e44.2)
28.3
(23.3e33.2)
62.4
(60.7e64.2)
63.1
(61.1e65.1)
27.6
(26.5e28.7)
16.6
(15.6e17.6)
d d
Males
Stage I 82.2
(75.0e89.5)
65.8
(40.4e91.2)
47.1 (22.6e71.6) 96.0 (90.9e101.) 93.4
(88.3e98.6)
50.1
(47.3e53.0)
63.9
(58.7e69.1)
d d
Stage II 69.3
(61.1e77.6)
57.2
(41.0e73.5)
49.0
(27.6e70.3)
87.3
(83.6e91.0)
81.4
(76.5e86.2)
34.7
(31.6e37.8)
36.8
(27.6e46.0)
d d
Stage III 48.6
(39.1e58.2)
44.4
(27.1e61.7)
45.8
(28.9e62.7)
66.1
(61.7e70.5)
63.0
(58.2e67.7)
11.0
(9.4e12.6)
12.2
(9.8e14.7)
d d
Stage IV 37.2
(32.0e42.4)
28.7
(21.1e36.3)
24.0
(18.2e29.9)
12.1
(9.2e15.0)
11.1
(7.6e14.6)
3.3
(1.5e5.2)
4.5
(3.5e5.5)
d d
(continued on next page)
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1086 C.-J. Chiang et al.registry in Taiwan to report incidence changes and stage-
specific relative survival estimates among adult cancer
patients. National coverage and the high data quality of the
cancer registry database not only provides accurate infor-
mation for policy planning, but also establishes a critical
foundation for academic research.
Our findings showed that most cancers among adult pa-
tients had a trend of increasing incidence, except for
cancers of the cervix uteri, bladder, stomach, nasopharynx,
and liver (Figure 2). In previous studies, a notable trend of
decreasing incidence was also observed for cervical,
stomach, and nasopharyngeal cancers during the period
between 1995 and 2006.5 The reasons for the decline in
incidence were attributed to a successful nationwide
screening program for cervical cancer, effective control of
Helicobacter pylori infection for stomach cancer, and
reduced consumption of salt-preserved foods for nasopha-
ryngeal cancer.5,15 Furthermore, liver cancer is one of the
most common malignant tumors and has been the leading
cause of cancer death in Taiwan. Chronic hepatitis B and/or
C infection are major causes of liver cancer, especially
hepatocellular carcinoma. The nationwide hepatitis B
vaccination program has been successful in preventing
acute and chronic liver disease in Taiwan since 198416,17
and an additional national viral hepatitis therapy program
was launched in Taiwan in October of 2003. Recent studies
have demonstrated that both the national immunization
program among vaccinated birth cohorts, which was
observed for 30 years, and the national viral hepatitis
therapy program, which was implemented among adults
aged 30e69 years, have significantly reduced the incidence
of and mortality from hepatocellular carcinoma in
Taiwan.18,19 This is why we found a decreasing incidence of
liver cancer during our study period. However, the exact
cause of the significant decline in the incidence of bladder
cancer is still not clear. The decrease might be attributable
to the promotion of The Surveillance, Epidemiology, and
End Results (SEER) Program multiple primary and histology
coding rule in 2007,20 but long-term surveillance and
further research are needed for clarification.
The Taiwanese government has launched national
screening programs for cancers of the colon and rectum,
female breast, and oral cavity and pharynx in the past
decade.21 Consistent with other studies,5 a steady
increased incidence in these screened cancers was also
observed in our study. Surprisingly, an annual increase in
incidence of >5% was observed in uterine cancer among
females, in prostate cancer among males, and in thyroid
cancers for both sexes. Because earlier menarche, delayed
childbearing, reduced fertility rates, and westernization of
lifestyles among Taiwanese women can lead to prolonged,
hyperestrogenic stimulation of the endometrium, and
phthalates are widely used in industry and consumer
products in Taiwan, these exogenous reasons and pollutants
have been reported to contribute to the exogenous estro-
gen effect, resulting in the incidence of uterine cancer.22
Thus, the rapid increasing incidence of uterine cancers in
Taiwanese women is likely due to excess endogenous es-
trogen exposure, obesity, and exogenous pollutants with
estrogenic effects.23 Prostate cancer was one of the most
increasingly diagnosed and leading cancers among males in
Taiwan.21 Although prostate specific antigen screening in
Incidence and survival of adult cancer patients 1087asymptomatic men is currently not implemented in Taiwan,
most prostate specific antigen screenings are performed in
general health examination settings.24 The reason for the
significantly increased incidence of prostate cancer may be
explained by the improvement in awareness of health ex-
aminations, aging populations, and high-fat diets.25 In
recent years, thyroid cancer has also been one of the top
five cancers among females, but the rapidly increasing
incidence was observed for both sexes in this study. After
the mandatory salt iodization program implemented in 1967
successfully corrected iodine deficiency in Taiwan, iodine
sufficiency has been maintained and provides an essential
element of thyroid hormones.26 However, there is emerging
evidence that Polybrominated diphenyl ethers (PBDEs) alter
thyroid hormone homeostasis and may cause thyroid
dysfunction,27 which may subsequently play a role in the
rapid increase in thyroid tumorigenesis. Furthermore, ad-
vances in head and neck ultrasonography, as well as its
wide use and applicability in Taiwan since 2008, may also
partially explain the observed increasing trend in thyroid
cancer.28 However, it is currently unclear whether the
observed increases in thyroid cancer are real, are due to
increased diagnosis, or both. These reasons need to be
evaluated further.
In terms of the distribution of stage at diagnosis, more
than half of oropharyngeal, hypopharyngeal, and lung
cancer patients received a diagnosis of Stage IV disease and
had worse survival. Because no universal screening program
has been implemented in Taiwan for these cancers, the
government should consider the promotion of early diag-
nosis of potential high-risk cases at earlier stages, such as
implementing the use of low-dose computed tomography
screening for lung cancer. A recent large international
comparison of population-based cancer survival (CONCORD-
2) found that Taiwan had higher 5-year RSRs for liver and
cervical cancers but similar survival rates for colorectal and
female breast cancers, when compared to Western coun-
tries.4 Although the time period in our study slightly
differed from the CONCORDS-2 study, the RSRs in this study
showed similar results. This may be explained by advances
in cancer detection and appropriate treatment for these
screened cancers in Taiwan.21,29
The strength of this analysis is the use of a large and
representative database: the analyses were based on cancer
data from a population-based cancer registry covering the
wholeTaiwanesepopulation. TheTCRhas high completeness,
high standard, and high quality of tumor documentation. In
addition, this study also used techniques for standard cohort
analysis and provided the most recent and comprehensive
survival estimates for major cancers in Taiwan. However,
there are some limitations of this study that should be noted
with caution. First, the validity of stage information is critical
for comparing cancer survival rates. Most cancer sites have
less than 7% of cases with unknown stage information, except
for cervical cancer. The reason for the difference is that most
gynecologists were accustomed to Federation Internationale
de Gynecologie et d’Obstetrique classification (FIGO) staging
rather thanAJCC staging at thebeginningof cancer stage data
collection. After AJCC staging was mandated beginning in
2007, the proportion of unknown staging in cases of cervical
cancer decreased from 28.8% in 2004 to 8.4% in 2008. Second,
the population-based cancer registry database may notcontain the variables needed to answer the research, clinical,
or policy questions being asked. Thus interpretations of study
findings should be cautious.
In conclusion, our study provides representative cancer
statistics regarding incidence changes and stage-specific
survival rates among adults aged 15 years and older in
Taiwan. Beginning in 2008, the Ministry of Health and
Welfare launched the Cancer Care Quality Accreditation
Program, and has since expanded the provision of cancer
screening services in 2010 to female breast, colorectal, and
oral cancers.21 The effect of these implemented policies
need to be evaluated in the future. Thus, establishing
baseline data, such as survival rates, for major cancers is
indispensable. The TCR database plays a critical role in
serving as the basis for the planning of cancer prevention
and control programs, as well as the basis for monitoring
surveillance and academic studies. Further research is
needed to identify factors related to increasing cancer
rates and the prognosis of certain cancers in Taiwan.Acknowledgments
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